Physician profile
Andrae Vandross
NPI 1205079373
$5,394.38
in general payments reported to CMS, 2019-2025
23 companies · $3,168 in 2025
The $3,168 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $44.69 · 2021: $107 · 2022: $430 · 2023: $385 · 2024: $1,083 · 2025: $3,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,088 · Travel and Lodging: $936 · Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,087.50 |
| Travel and Lodging | $935.64 |
| Food and Beverage | $613.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,067.76 | 2024-2025 | |
| Exelixis INC. | $318.79 | 2022-2023 | Cabometyx |
| Janssen Biotech, INC. | $200.94 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Deciphera Pharmaceuticals INC. | $148.61 | 2022-2024 | Qinlock |
| Mirati Therapeutics, INC. | $109.34 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $95.79 | 2023 | |
| Tempus Ai, INC | $49.84 | 2024 | |
| Novartis Pharmaceuticals Corporation | $40.30 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $33.77 | 2024 | |
| Daiichi Sankyo INC. | $30.06 | 2020 | |
| Pfizer INC. | $25.94 | 2019 | |
| Merck Sharp & Dohme LLC | $22.81 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.03 | 2025 | Adstiladrin |
| Ipsen Biopharmaceuticals, INC | $19.09 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $16.47 | 2022 | |
| Blueprint Medicines Corporation | $15.04 | 2025 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $14.63 | 2020 | |
| Genentech USA, INC. | $14.17 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrae Vandross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.